Related Experiment Video

Updated: Jul 7, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy

Dharmesh A Patel¹, Siddharth S Patel¹, Hitesh D Patel¹

¹Department of Chemistry, School of Sciences, Gujarat University, Navarangpura, Ahmedabad, Gujarat, India.

Bioorganic Chemistry

|December 26, 2023

Abstract:

One of the leading causes of mortality in the world is cancer. This disease occurs when responsible genes that regulate the cell cycle become inactive due to internal or external factors. Specifically, the G1/S and S/G2 transitions in the cell cycle are controlled by a protein called cyclin-dependent kinase 2 (CDK2). CDKs, which play a crucial role in managing the cell cycle, have been a wide area of research in cancer treatment. Over the past 11 years, significant research has been made in identifying potent, targeted, and efficient inhibitors of CDK2. In this summary, we have summarized recent developments in the synthesis and biological evaluation of CDK2 inhibitors.

Insights

Researchers are developing new CDK2 inhibitors to combat cancer. This summary highlights recent advancements in synthesizing and evaluating these targeted cancer therapies.

Area of Science:

Oncology
Molecular Biology
Drug Discovery

Background:

Cancer is a leading global cause of mortality.
Dysregulation of cell cycle genes contributes to cancer development.
Cyclin-dependent kinase 2 (CDK2) controls critical cell cycle transitions (G1/S and S/G2).

Purpose of the Study:

To summarize recent developments in the synthesis of CDK2 inhibitors.
To review the biological evaluation of novel CDK2 inhibitors.
To highlight progress in targeted cancer therapy research.

Main Methods:

Review of scientific literature on CDK2 inhibitor synthesis.
Analysis of biological data from evaluated CDK2 inhibitors.
Synthesis and characterization of potential drug candidates.

Main Results:

Identification of potent and targeted CDK2 inhibitors.
Demonstration of efficient biological activity of novel compounds.
Progress in developing specific inhibitors for cancer treatment.

Conclusions:

CDK2 inhibitors represent a promising area for cancer treatment development.
Recent research has yielded significant advancements in inhibitor design and evaluation.
Targeted inhibition of CDK2 offers a potential strategy for effective cancer therapy.

Read full analysis

Keywords:

Anticancer Antiproliferative activity CDK2 enzyme CDK2 inhibitor Cell cycle arrest

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Articles linked to this work by shared authors, journal, and citation graph.

Investigating the Osteoprotective Potential of Holoptelia integrefolia through Multitarget Modulation of Bone Metabolic Pathways.

Applied biochemistry and biotechnology·2026

Discovery of Potent CDK2 Inhibitors Through Structure-Based Virtual Screening and MD Simulation Studies.

Biotechnology and applied biochemistry·2026

Design, synthesis, antimicrobial evaluation, and molecular dynamics-based computational investigation of novel imidazole-based FabI-targeted derivatives with antioxidant, DNA nicking, and cytotoxicity studies.

Bioorganic chemistry·2026

Corrigendum to: A Comprehensive Review of Nanomaterials as Potential Weapons against Multidrug-resistant Staphylococcus aureus.

Pharmaceutical nanotechnology·2026

Design, synthesis, antimicrobial and antioxidant evaluation, cytotoxicity assessment, and molecular dynamics-based computational studies of novel PABA analogues as dual DHPS/DHFR inhibitors.

RSC advances·2026

Design, computational profiling, synthesis and biological evaluation of novel 1,2,4-triazole based derivatives as antioxidant and potent p53-MDM2 inhibitors.

Bioorganic chemistry·2026

See all related articles